IBDEI1H3 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,26421,1,3,0)
 ;;=3^99070
 ;;^UTILITY(U,$J,358.3,26422,0)
 ;;=99080^^156^1608^47^^^^1
 ;;^UTILITY(U,$J,358.3,26422,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26422,1,2,0)
 ;;=2^Special Reports or Forms
 ;;^UTILITY(U,$J,358.3,26422,1,3,0)
 ;;=3^99080
 ;;^UTILITY(U,$J,358.3,26423,0)
 ;;=G9169^^156^1608^34^^^^1
 ;;^UTILITY(U,$J,358.3,26423,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26423,1,2,0)
 ;;=2^Memory Goal Status
 ;;^UTILITY(U,$J,358.3,26423,1,3,0)
 ;;=3^G9169
 ;;^UTILITY(U,$J,358.3,26424,0)
 ;;=G9170^^156^1608^33^^^^1
 ;;^UTILITY(U,$J,358.3,26424,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26424,1,2,0)
 ;;=2^Memory D/C Status
 ;;^UTILITY(U,$J,358.3,26424,1,3,0)
 ;;=3^G9170
 ;;^UTILITY(U,$J,358.3,26425,0)
 ;;=G9165^^156^1608^8^^^^1
 ;;^UTILITY(U,$J,358.3,26425,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26425,1,2,0)
 ;;=2^Attention Current Status
 ;;^UTILITY(U,$J,358.3,26425,1,3,0)
 ;;=3^G9165
 ;;^UTILITY(U,$J,358.3,26426,0)
 ;;=G9166^^156^1608^10^^^^1
 ;;^UTILITY(U,$J,358.3,26426,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26426,1,2,0)
 ;;=2^Attention Goal Status
 ;;^UTILITY(U,$J,358.3,26426,1,3,0)
 ;;=3^G9166
 ;;^UTILITY(U,$J,358.3,26427,0)
 ;;=G9167^^156^1608^9^^^^1
 ;;^UTILITY(U,$J,358.3,26427,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26427,1,2,0)
 ;;=2^Attention D/C Status
 ;;^UTILITY(U,$J,358.3,26427,1,3,0)
 ;;=3^G9167
 ;;^UTILITY(U,$J,358.3,26428,0)
 ;;=20600^^156^1609^6^^^^1
 ;;^UTILITY(U,$J,358.3,26428,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26428,1,2,0)
 ;;=2^Asp/Inj Small Jt w/o US
 ;;^UTILITY(U,$J,358.3,26428,1,3,0)
 ;;=3^20600
 ;;^UTILITY(U,$J,358.3,26429,0)
 ;;=20605^^156^1609^2^^^^1
 ;;^UTILITY(U,$J,358.3,26429,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26429,1,2,0)
 ;;=2^Asp/Inj Intermediate Jt w/o US
 ;;^UTILITY(U,$J,358.3,26429,1,3,0)
 ;;=3^20605
 ;;^UTILITY(U,$J,358.3,26430,0)
 ;;=20610^^156^1609^4^^^^1
 ;;^UTILITY(U,$J,358.3,26430,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26430,1,2,0)
 ;;=2^Asp/Inj Major Jt w/o US
 ;;^UTILITY(U,$J,358.3,26430,1,3,0)
 ;;=3^20610
 ;;^UTILITY(U,$J,358.3,26431,0)
 ;;=20550^^156^1609^9^^^^1
 ;;^UTILITY(U,$J,358.3,26431,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26431,1,2,0)
 ;;=2^Inject Tendon/Ligament/Cyst 
 ;;^UTILITY(U,$J,358.3,26431,1,3,0)
 ;;=3^20550
 ;;^UTILITY(U,$J,358.3,26432,0)
 ;;=J1100^^156^1609^8^^^^1
 ;;^UTILITY(U,$J,358.3,26432,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26432,1,2,0)
 ;;=2^Dexamethasone Sodium Phos 1 mg
 ;;^UTILITY(U,$J,358.3,26432,1,3,0)
 ;;=3^J1100
 ;;^UTILITY(U,$J,358.3,26433,0)
 ;;=J0800^^156^1609^7^^^^1
 ;;^UTILITY(U,$J,358.3,26433,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26433,1,2,0)
 ;;=2^Corticotropin Inj up to 40 units
 ;;^UTILITY(U,$J,358.3,26433,1,3,0)
 ;;=3^J0800
 ;;^UTILITY(U,$J,358.3,26434,0)
 ;;=J1040^^156^1609^10^^^^1
 ;;^UTILITY(U,$J,358.3,26434,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26434,1,2,0)
 ;;=2^Methylprednisolone 80 Mg Inj
 ;;^UTILITY(U,$J,358.3,26434,1,3,0)
 ;;=3^J1040
 ;;^UTILITY(U,$J,358.3,26435,0)
 ;;=20606^^156^1609^1^^^^1
 ;;^UTILITY(U,$J,358.3,26435,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26435,1,2,0)
 ;;=2^Asp/Inj Intermediate Jt w/ US
 ;;^UTILITY(U,$J,358.3,26435,1,3,0)
 ;;=3^20606
 ;;^UTILITY(U,$J,358.3,26436,0)
 ;;=20611^^156^1609^3^^^^1
 ;;^UTILITY(U,$J,358.3,26436,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,26436,1,2,0)
 ;;=2^Asp/Inj Major Jt w/ US
 ;;^UTILITY(U,$J,358.3,26436,1,3,0)
 ;;=3^20611
 ;;^UTILITY(U,$J,358.3,26437,0)
 ;;=20604^^156^1609^5^^^^1
 ;;^UTILITY(U,$J,358.3,26437,1,0)
 ;;=^358.31IA^3^2
